Genmab — Marts 2025
-
Der er et utal af juridiske slagsmål og retstvister om stort og småt indenfor pharma, biotek og medico. Antallet af sager er eskaleret eksplosivt siden 1990´erne.
-
De må jo gære noget så ikke deres $10bn køb i 2023 ikke ser helt håbløs ud https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen,-including-its-Flagship-Cancer-Therapy-ELAHERE-R-mirvetuximab-soravtansine-gynx-,-Expanding-Solid-Tumor-Portfolio For mig at se er det et kæmpe problem for Elahere, at der er “ Fatal adverse reactions occurred in 2% of patients” https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen,-including-its-Flagship-Cancer-Therapy-ELAHERE-R-mirvetuximab-soravtan
-
Genmabs langsigtede salgsprognoser https://proinvestor.com/boards/125146
-
Godmorgen
-
Genmab sagsøges for misbrug af forretningshemmeligheder https://proinvestor.com/investornyt/1294524/genmab-sagsoges-for-misbrug-af-forretningshemmeligheder
-
Problemet er, at vi nu skal leve med et par års usikkerhed før denne tvist er afgjort!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind